Review of the experience of using herbal drugs for the treatment of acute rhinosinusitis from the standpoint of evidence-based medicine
- Authors: Bachert C.1
-
Affiliations:
- University Hospital Ghent
- Issue: Vol 23, No 9 (2021)
- Pages: 430-440
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95496
- DOI: https://doi.org/10.26442/20751753.2021.9.200988
- ID: 95496
Cite item
Full Text
Abstract
General background. The overuse of antibiotics, including for the treatment of uncomplicated acute rhinosinusitis (ARS), has contributed to the emergence of antibiotic-resistant bacterial strains and has led to the need for alternative therapies. The review provides an assessment of the quality of evidence for the use of phytotherapy in ARS in order to determine its position among other therapies and future directions of research. The MEDLINE database was searched for randomized controlled studies of Sinupret®, Pelargonium sidoides extract (pelargonium), Cyclamen europaeum (cyclamen), cineole and GeloMyrtol®. We also searched for results from studies of a nasal spray with N-acetylcysteine and mometasone furoate (MF) in order to compare the effectiveness of herbal preparations with these traditional agents indicated for ARS. Main content. The strongest evidence was obtained for Sinupret®, followed by Pelargonium sidoides extract. Their use for treatment of ARS is supported by double-blind, placebo-controlled studies demonstrating both clinical efficacy and safety. Comparisons with traditional treatments such as topical glucocorticosteroids were found only for Sinupret® and they showed comparable efficacy, but in a small group of patients. For other herbal drugs, the pooled level of evidence was low. The search identified 2 small, placebo-controlled, randomized studies of cyclamen nasal spray. In two studies, it was impossible to make conclusions about the safety and efficacy of cyclamen nasal spray and reported no efficacy of cyclamen in reducing symptoms. We found only one randomized placebo-controlled study of GeloMyrtol® and cineol. The mention studies have showed a reduction in ARS symptoms with these two drugs, but larger studies are needed to confirm these findings. There are few studies that directly compared herbal drugs. In one randomized study, cineol was compared with Sinupret®, but the results need to be confirmed in further studies. Studies of N-acetylcysteine are limited to small clinical trials, while the use of MF nasal spray has been confirmed with results comparable in evidence to Sinupret® for the respective indications. Conclusions. There are modern studies that demonstrate the efficacy and safety of herbal drugs for ARS treatment. Given that the evidence for Sinupret® is the strongest and comparable to that for the widely available topical corticosteroid, MF, Sinupret could be considered for the treatment of uncomplicated ARS.
Full Text
##article.viewOnOriginalSite##About the authors
Claus Bachert
University Hospital Ghent
Email: claus.bachert@ugent.be
профессор, глава лаборатории исследования верхних дыхательных путей Ghent, Belgium
References
- Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1-12. doi: 10.4193/Rhino50E2
- Worrall G. Acute sinusitis. Can Fam Physician. 2011;57:56577.
- Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: rhinosinusitis executive summary. Int Forum Allergy Rhinol. 2016;6(Suppl. 1):S3-21. doi: 10.1002/alr.21694
- Sharma P, Finley R, Weese S, et al. Antibiotic prescriptions for outpatient acute rhinosinusitis in Canada, 2007-2013. PLoS One. 2017;12:e0181957. doi: 10.1371/journal.pone.0181957
- Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 19901997: results of a follow-up national survey. JAMA. 1998;280:1569-75. doi: 10.1001/jama.280.18.1569
- Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of allergic rhinitis: a systematic review. Ann Allergy Asthma Immunol. 2007;99:483-95. doi: 10.1016/S1081-1206(10)60375-4
- Koch AK, Klose P, Lauche R, et al. A systematic review of phytotherapy for acute rhinosinusitis. Forsch Komplementmed. 2016;23:165-9. doi: 10.1159/000447467
- Macchi A, Terranova P, Castelnuovo P. Recurrent acute rhinosinusitis: a single blind clinical study of N-acetylcysteine vs ambroxol associated to corticosteroid therapy. Int J Immunopathol Pharmacol. 2012;25:207-17. doi: 10.1177/039463201202500123
- Neubauer N, Marz RW. Placebo-controlled, randomized double-blind clinical trial with Sinupret(R) sugar coated tablets on the basis of a therapy with antibiotics and decongestant nasal drops in acute sinusitis. Phytomedicine. 1994;1:177-81. doi: 10.1016/S0944-7113(11)80061-9
- Rossi A, Dehm F, Kiesselbach C, et al. The novel Sinupret(R) dry extract exhibits antiinflammatory effectiveness in vivo. Fitoterapia. 2012;83:715720. doi: 10.1016/j.fitote.2012.02.008
- Marz RW, Ismail C, Popp MA. Profile and effectiveness of a phytogenic combination preparation for treatment of sinusitis. Wien Med Wochenschr. 1999;149:202-8.
- Melzer J, Saller R, Schapowal A, Brignoli R. Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis. Forsch Komplementmed. 2006;13:78-87. doi: 10.1159/000091969
- Jund R, Mondigler M, Stammer H, et al. Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis. Acta Otolaryngol. 2015;135:42-50. doi: 10.3109/00016489.2014.952047
- Jund R, Mondigler M, Steindl H, et al. Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis. Rhinology. 2012;50:417-26. doi: 10.4193/Rhino12.015
- Jund R, Mondigler M, Steindl H, et al. Clinical efficacy of a herbal drug combination in acute viral rhinosinusitis. MMW Fortschr Med. 2015;157:6-11. doi: 10.1007/s15006-015-2934-4
- Passali D, Loglisci M, Passali GC, et al. A prospective open-label study to assess the efficacy and safety of a herbal medicinal product (Sinupret) in patients with acute rhinosinusitis. ORL J Otorhinolaryngol Relat Spec. 2015;77:27-32. D0I:10.1159/000370123
- Weber U, Luedtke R, Friese KH, et al. A non-randomised pilot study to compare complementary and conventional treatments of acute sinusitis. Forsch Komplementarmed Klass Naturheilkd. 2002;9:99-104. doi: 10.1159/000057271
- Schoetz K, Erdelmeier C, Germer S, Hauer H. A detailed view on the constituents of EPs 7630. Planta Med. 2008;74:667-74. doi: 10.1055/s-2008-1074515
- Bladt S, Wagner H. From the Zulu medicine to the European phytomedicine Umckaloabo. Phytomedicine. 2007;14(Suppl. 6):2-4. DOI:10.1016/j. phymed.2006.11.030
- Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. Phytother Res. 2001;15:122-6. doi: 10.1002/ptr.785
- Michaelis M, Doerr HW, Cinatl J Jr. Investigation of the influence of EPs(R) 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine. 2011;18:384-6. doi: 10.1016/j.phymed.2010.09.008
- Lizogub VG, Riley DS, Heger M. Efficacy of a Pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore (NY). 2007;3:573-84. D0I:10.1016/j.explore.2007.09.004
- Riley DS, Lizogub VG, Zimmermann A, et al. Efficacy and tolerability of high-dose pelargonium extract in patients with the common cold. Altern Ther Health Med. 2018;24:16-26.
- Bachert C, Schapowal A, Funk P, Kieser M. Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial. Rhinology. 2009;47:51-8.
- Peric A, Gacesa D, Barac A, et al. Herbal drug EPs 7630 versus amoxicillin in patients with uncomplicated acute bacterial rhinosinusitis: a randomized, open-label study. Ann Otol Rhinol Laryngol. 2020;129:969-76. doi: 10.1177/0003489420918266
- Mullol J, Crespo C, Carre C, Brosa M. Pharmacoeconomics of Cyclamen europaeum in the management of acute rhinosinusitis. Laryngoscope. 2013;123:2620-5. doi: 10.1002/lary.24167
- Pfaar O, Mullol J, Anders C, et al. Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo-controlled trial. Rhinology. 2012;50(1):37-44. doi: 10.4193/Rhino10.096
- Ponikau JU, Hamilos DL, Barreto A, et al. An exploratory trial of Cyclamen europaeum extract for acute rhinosinusitis. Laryngoscope. 2012;122:1887-92. doi: 10.1002/lary.23366
- Gedevanishvili MD, Gogitidze NM, Sikharulidze IS. Reflex mechanisms of nasoparanasal secretion in administration of sinuforte. Vestn Otorinolaringol. 2007;(3):54-5.
- Zalmanovici Trestioreanu A, Barua A, Pertzov B. Cyclamen europaeum extract for acute sinusitis. Cochrane Database SystRev. 2018;5:CD011341. D0I:10.1002/14651858.CD011341.pub2
- Gottschlich S, Roschmann K, Candler H. Phytomedicines in acute rhinosinusitis: a prospective, non-interventional parallel-group trial. Adv Ther. 2018;35:1023-34. doi: 10.1007/s12325-018-0736-7
- Rantzsch U, Vacca G, Duck R, Gillissen A. Anti-inflammatory effects of Myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease. Eur J Med Res. 2009;14(Suppl. 4):205-9. doi: 10.1186/2047-783x-14-s4-205
- Christoph F, Kaulfers PM, Stahl-Biskup E. In vitro evaluation of the antibacterial activity of betatriketones admixed to Melaleuca oils. Planta Med. 2001;67:768-71. doi: 10.1055/s-2001-18350
- Behrbohm H, Kaschke O, Sydow K. Effect of the phytogenic secretolytic drug Gelomyrtol forte on mucociliary clearance of the maxillary sinus. Laryngorhinootologie. 1995;74:733-7. doi: 10.1055/s-2007-997835
- Meister R, Wittig T, Beuscher N, de Mey C. Efficacy and tolerability of myrtol standardized in longterm treatment of chronic bronchitis. A double-blind, placebo-controlled study. Study Group Investigators. Arzneimittelforschung. 1999;49:351-8. doi: 10.1055/s-0031-1300426
- Gillissen A, Wittig T, Ehmen M, et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trial on the efficacy and tolerability of GeloMyrtol(R) forte in acute bronchitis. Drug Res (Stuttg). 2013;63:19-27. doi: 10.1055/s-0032-1331182
- Federspil P, Wulkow R, Zimmermann T. Effects of standardized Myrtol in therapy of acute sinusitis - results of a double-blind, randomized multicenter study compared with placebo. Laryngorhinootologie. 1997;76:2377. doi: 10.1055/s-2007-997381
- Kehrl W, Sonnemann U, Dethlefsen U. Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial. Laryngoscope. 2004;114:738-42. DOI:10.1097/ 00005537-200404000-00027
- Paparoupa M, Gillissen A. Is Myrtol(R) standardized a new alternative toward antibiotics? Pharma-cogn Rev. 2016;10:143-6. doi: 10.4103/0973-7847.194045
- Aldoghaim FS, Flematti GR, Hammer KA. Antimicrobial activity of several ineole-rich Western Australian Eucalyptus essential oils. Microorganisms. 2018;6. doi: 10.3390/microorganisms6040122
- Yadav N, Chandra H. Suppression of inflammatory and infection responses in lung macrophages by eucalyptus oil and its constituent 1,8-cineole: role of pattern recognition receptors TREM-1 and NLRP3, the MAP kinase regulator MKP-1, and NFkappaB. PLoS One. 2017;12:e0188232. doi: 10.1371/journal.pone.0188232
- Juergens UR. Anti-inflammatory properties of the monoterpene 1.8-cineole: urrent evidence for co-medication in inflammatory airway diseases. Drug Res (Stuttg). 2014;64:638-46. doi: 10.1055/s-0034-1372609
- Tesche S, Metternich F, Sonnemann U, et al. The value of herbal medicines in the treatment of acute non-purulent rhinosinusitis. Results of a double-blind, randomised, controlled trial. Eur Arch Otorhinolaryngol. 2008;265:1355-9. doi: 10.1007/s00405-008-0683-z
- Bachert C, Thakur M, Weyers S, et al. Reporting clinical trial results of phytomedicines in acute rhinosinusitis: letter to the editor regarding Gottschlich S, Roschmann K, Candler H. Adv Ther (2018); 35:1023-1034. doi: 10.1007/s12325-018-0736-7. Adv Ther. 2019;36:1011-3. doi: 10.1007/s12325-019-00933-6
- Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016;11:18. doi: 10.1186/s40248-016-0054-3
- Meltzer EO, Charous BL, Busse WW, et al. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. J Allergy Clin Immunol. 2000;106:630-7. doi: 10.1067/mai.2000.109056
- Nayak AS, Settipane GA, Pedinoff A, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol. 2002;89:271-8. doi: 10.1016/S1081-1206(10)61954-0
- Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116:1289-95. doi: 10.1016/j.jaci.2005.08.044
- Bachert C, Meltzer EO. Effect of mometasone furoate nasal spray on quality of life of patients with acute rhinosinusitis. Rhinology. 2007;45:190-6.
- Meltzer EO, Gates D, Bachert C. Mometasone furoate nasal spray increases the number of minimal-symptom days in patients with acute rhinosinusitis. Ann Allergy Asthma Immunol. 2012;108:275-9. doi: 10.1016/j.anai.2012.01.015
- Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev. 2013:CD005149. DOI:10.1002/ 14651858.CD005149.pub4
- Blasi F, Page C, Rossolini GM, et al. The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190-7. doi: 10.1016/j.rmed.2016.06.015
- Sadowska AM, Verbraecken J, Darquennes K, De Backer WA. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:425-34. doi: 10.2147/copd.2006.1.4.425
- Bahtouee M, Monavarsadegh G, Ahmadipour M, et al. Acetylcysteine in the treatment of subacute sinusitis: a double-blind placebo-controlled clinical trial. Ear Nose Throat J. 2017;96:E7-11. doi: 10.1177/014556131709600102.